| Pair Name | Proanthocyanidin, Histone deacetylase inhibitor | ||
| Phytochemical Name | Proanthocyanidin (PubChem CID: 108065 ) | ||
| Anticancer drug Name | Histone deacetylase inhibitor (PubChem CID: 10095659 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Proanthocyanidin, Histone deacetylase inhibitor | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | MMRN1 | hsa22915 |
| In Vitro Model | T-47D | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0553 |
| MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
| Result | Their synergism may be closely related to the steroid biosynthesis and extracellular matrix (ECM) receptor interaction pathways. PA + Chi can synergistically inhibit breast cancer cell growth and proliferation, and promote apoptosis. These effects may be related to steroid biosynthesis or the ECM receptor pathway. | |||
| No. | Title | Href |
|---|---|---|
| 1 | The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis. Int J Mol Sci. 2023 Jun 22;24(13):10476. doi: 10.3390/ijms241310476. | Click |
